Publications

BibTex format

@article{Ferreira:2019:10.1007/s00392-019-01578-9,
author = {Ferreira, JP and Duarte, K and Woehrle, H and Cowie, MR and Angermann, C and d'Ortho, M-P and Erdmann, E and Levy, P and Simonds, AK and Somers, VK and Teschler, H and Wegscheider, K and Bresso, E and Dominique-Devignes, M and Rossignol, P and Koenig, W and Zannad, F},
doi = {10.1007/s00392-019-01578-9},
journal = {Clinical Research in Cardiology},
pages = {1--11},
title = {Bioprofiles and mechanistic pathways associated with Cheyne-Stokes respiration: insights from the SERVE-HF trial},
url = {http://dx.doi.org/10.1007/s00392-019-01578-9},
year = {2019}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - IntroductionThe SERVE-HF trial included patients with heart failure and reduced ejection fraction (HFrEF) with sleep-disordered breathing, randomly assigned to treatment with Adaptive-Servo Ventilation (ASV) or control. The primary outcome was the first event of death from any cause, lifesaving cardiovascular intervention, or unplanned hospitalization for worsening heart failure. A subgroup analysis of the SERVE-HF trial suggested that patients with Cheyne-Stokes respiration (CSR) < 20% (low CSR) experienced a beneficial effect from ASV, whereas in patients with CSR ≥ 20% ASV might have been harmful. Identifying the proteomic signatures and the underlying mechanistic pathways expressed in patients with CSR could help generating hypothesis for future research.MethodsUsing a large set of circulating protein-biomarkers (n = 276, available in 749 patients; 57% of the SERVE-HF population) we sought to investigate the proteins associated with CSR and to study the underlying mechanisms that these circulating proteins might represent.ResultsThe mean age was 69 ± 10 years and > 90% were male. Patients with CSR < 20% (n = 139) had less apnoea-hypopnea index (AHI) events per hour and less oxygen desaturation. Patients with CSR < 20% might have experienced a beneficial effect of ASV treatment (primary outcome HR [95% CI] = 0.55 [0.34–0.88]; p = 0.012), whereas those with CSR ≥ 20% might have experienced a detrimental effect of ASV treatment (primary outcome HR [95% CI] = 1.39 [1.09–1.76]; p = 0.008); p for interaction = 0.001. Of the 276 studied biomarkers, 8 were associated with CSR (after adjustment and with a FDR1%-corrected p value). For example, higher PAR-1 and ITGB2 levels were associated with higher odds of having CSR < 20%
AU  - Ferreira,JP
AU  - Duarte,K
AU  - Woehrle,H
AU  - Cowie,MR
AU  - Angermann,C
AU  - d'Ortho,M-P
AU  - Erdmann,E
AU  - Levy,P
AU  - Simonds,AK
AU  - Somers,VK
AU  - Teschler,H
AU  - Wegscheider,K
AU  - Bresso,E
AU  - Dominique-Devignes,M
AU  - Rossignol,P
AU  - Koenig,W
AU  - Zannad,F
DO  - 10.1007/s00392-019-01578-9
EP  - 11
PY  - 2019///
SN  - 0300-5860
SP  - 1
TI  - Bioprofiles and mechanistic pathways associated with Cheyne-Stokes respiration: insights from the SERVE-HF trial
T2  - Clinical Research in Cardiology
UR  - http://dx.doi.org/10.1007/s00392-019-01578-9
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000499431900003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://link.springer.com/article/10.1007%2Fs00392-019-01578-9
ER  -

Download

ProfessorMartinCowie

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)